The Addition of Salmeterol 50 µg Bid to Anticholinergenic Treatment in Patients with COPD: A Randomized Placebo Controlled Trial
BACKGROUND: In the past, the role of long-acting beta2-agonists in chronic obstructive pulmonary disease (COPD) relative to other agents has been unclear.
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2002-01-01
|
| Series: | Canadian Respiratory Journal |
| Online Access: | http://dx.doi.org/10.1155/2002/493296 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550506832068608 |
|---|---|
| author | Kenneth R Chapman Peter Arvidsson AG Chuchalin DP Dhillon Peter Faurschou Roger S Goldstein AF Kuipers |
| author_facet | Kenneth R Chapman Peter Arvidsson AG Chuchalin DP Dhillon Peter Faurschou Roger S Goldstein AF Kuipers |
| author_sort | Kenneth R Chapman |
| collection | DOAJ |
| description | BACKGROUND: In the past, the role of long-acting beta2-agonists in chronic obstructive pulmonary disease (COPD) relative to other agents has been unclear. |
| format | Article |
| id | doaj-art-98cfee3d95854d51aa9ac1df60dc9791 |
| institution | Kabale University |
| issn | 1198-2241 |
| language | English |
| publishDate | 2002-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Respiratory Journal |
| spelling | doaj-art-98cfee3d95854d51aa9ac1df60dc97912025-02-03T06:06:39ZengWileyCanadian Respiratory Journal1198-22412002-01-019317818510.1155/2002/493296The Addition of Salmeterol 50 µg Bid to Anticholinergenic Treatment in Patients with COPD: A Randomized Placebo Controlled TrialKenneth R Chapman0Peter Arvidsson1AG Chuchalin2DP Dhillon3Peter Faurschou4Roger S Goldstein5AF Kuipers6Toronto Western Hospital, Toronto, Ontario, CanadaSahlgrenska University Hospital, Gothenburg, SwedenPulmonology Research Institute, Moscow, RussiaWalsgrave Hospital, Coventry, UKKas Gentofte Lungemedicinsk Afeling Y, Hellerup, DenmarkWest Park Hospital, Toronto, Ontario, CanadaIsala Klinieken, Zwolle, The NetherlandsBACKGROUND: In the past, the role of long-acting beta2-agonists in chronic obstructive pulmonary disease (COPD) relative to other agents has been unclear.http://dx.doi.org/10.1155/2002/493296 |
| spellingShingle | Kenneth R Chapman Peter Arvidsson AG Chuchalin DP Dhillon Peter Faurschou Roger S Goldstein AF Kuipers The Addition of Salmeterol 50 µg Bid to Anticholinergenic Treatment in Patients with COPD: A Randomized Placebo Controlled Trial Canadian Respiratory Journal |
| title | The Addition of Salmeterol 50 µg Bid to Anticholinergenic Treatment in Patients with COPD: A Randomized Placebo Controlled Trial |
| title_full | The Addition of Salmeterol 50 µg Bid to Anticholinergenic Treatment in Patients with COPD: A Randomized Placebo Controlled Trial |
| title_fullStr | The Addition of Salmeterol 50 µg Bid to Anticholinergenic Treatment in Patients with COPD: A Randomized Placebo Controlled Trial |
| title_full_unstemmed | The Addition of Salmeterol 50 µg Bid to Anticholinergenic Treatment in Patients with COPD: A Randomized Placebo Controlled Trial |
| title_short | The Addition of Salmeterol 50 µg Bid to Anticholinergenic Treatment in Patients with COPD: A Randomized Placebo Controlled Trial |
| title_sort | addition of salmeterol 50 µg bid to anticholinergenic treatment in patients with copd a randomized placebo controlled trial |
| url | http://dx.doi.org/10.1155/2002/493296 |
| work_keys_str_mv | AT kennethrchapman theadditionofsalmeterol50μgbidtoanticholinergenictreatmentinpatientswithcopdarandomizedplacebocontrolledtrial AT peterarvidsson theadditionofsalmeterol50μgbidtoanticholinergenictreatmentinpatientswithcopdarandomizedplacebocontrolledtrial AT agchuchalin theadditionofsalmeterol50μgbidtoanticholinergenictreatmentinpatientswithcopdarandomizedplacebocontrolledtrial AT dpdhillon theadditionofsalmeterol50μgbidtoanticholinergenictreatmentinpatientswithcopdarandomizedplacebocontrolledtrial AT peterfaurschou theadditionofsalmeterol50μgbidtoanticholinergenictreatmentinpatientswithcopdarandomizedplacebocontrolledtrial AT rogersgoldstein theadditionofsalmeterol50μgbidtoanticholinergenictreatmentinpatientswithcopdarandomizedplacebocontrolledtrial AT afkuipers theadditionofsalmeterol50μgbidtoanticholinergenictreatmentinpatientswithcopdarandomizedplacebocontrolledtrial AT kennethrchapman additionofsalmeterol50μgbidtoanticholinergenictreatmentinpatientswithcopdarandomizedplacebocontrolledtrial AT peterarvidsson additionofsalmeterol50μgbidtoanticholinergenictreatmentinpatientswithcopdarandomizedplacebocontrolledtrial AT agchuchalin additionofsalmeterol50μgbidtoanticholinergenictreatmentinpatientswithcopdarandomizedplacebocontrolledtrial AT dpdhillon additionofsalmeterol50μgbidtoanticholinergenictreatmentinpatientswithcopdarandomizedplacebocontrolledtrial AT peterfaurschou additionofsalmeterol50μgbidtoanticholinergenictreatmentinpatientswithcopdarandomizedplacebocontrolledtrial AT rogersgoldstein additionofsalmeterol50μgbidtoanticholinergenictreatmentinpatientswithcopdarandomizedplacebocontrolledtrial AT afkuipers additionofsalmeterol50μgbidtoanticholinergenictreatmentinpatientswithcopdarandomizedplacebocontrolledtrial |